Lonza has announced its new streamlined operating model, effective today. Lonza’s new One Lonza vision and strategy, centered around the Lonza Engine, which brings together the company’s core competencies.

The Lonza Engine comprises five key components including: high performance teams; its scientific, technological and digital ecosystem; customer partnerships; end-to-end execution; and plug-and-play investment and integration capabilities. The simplified One Lonza organization aims to enhance customer experience, provide scalability for future growth and strengthen Lonza’s multimodality offering.

Lonza’s offering comprises three newly-formed CDMO Business Platforms:

Integrated Biologics, led by Gordon Bates, aims to advance Lonza’s integrated offering and comprises Mammalian and Drug Product Services.

Advanced Synthesis, led by Christian Seufert, combines leading hybrid chemistry and biology solutions and comprises the former Small Molecules division and Bioconjugates.

Specialized Modalities, led by Daniel Palmacci, pioneers and scales technologies including Cell & Gene Technologies, mRNA, Microbial, and Bioscience. 

Within the new structure, the business unit layer has been removed, and the three business platforms now each directly manage multiple technology platforms. The Capsules & Health Ingredients (CHI) business will continue to operate in its existing structure.

The new organizational structure aim to further enable Lonza to capture growth opportunities by empowering key Group Functions and improving execution capabilities, including a unified go-to-market approach and an increased focus on excellence in asset construction and operation.

Continuing to operate in its current structure, the CHI business is now led by Jean-Christophe Hyvert. Lonza plans to part ways with the business at the appropriate time, while ensuring CHI continues to serve its customers and deliver profitable growth.